Poseida Therapeutics, Inc. |
Rajesh Belani |
Clinical Trial Stage Projects |
Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma |
$19,813,407 |
University of California, Davis |
Gerhard Bauer |
Conference - Manage The SPARK Annual Meeting |
The 2018 SPARK Annual Meeting |
$39,391 |
California State University San Marcos Corporation |
Bianca Mothe |
Conference - Manage The Bridges Annual Meeting |
2018 and 2019 Bridges Annual Meeting |
$291,622 |
RUNX1 Research Program |
Timothy Babich |
Conference II |
Living with and Curing RUNX1 FPD/AML Forum |
$9,500 |
Alliance Forum Foundation |
George Hara |
Conference II |
2017 World Alliance Forum in San Francisco (WAFSF) "Healthcare Game Changers" |
$5,000 |
Nohla Therapeutics Inc |
Colleen Delaney |
Clinical Trial Stage Projects |
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML |
$4,310,000 |
ViaCyte, Inc. |
Manasi Jaiman |
Clinical Trial Stage Projects |
Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes |
$13,607,002 |
Humacyte, Inc. |
Jeffrey Lawson |
Clinical Trial Stage Projects |
A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End-Stage Renal Disease (California Sites) |
$3,525,000 |
City of Hope, Beckman Research Institute |
Christine Brown |
Clinical Trial Stage Projects |
Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
University of California, Davis |
Mehrdad Abedi |
Alpha Stem Cell Clinics Network Expansion |
Alpha Stem Cell Clinic for Northern and Central California |
$8,076,421 |
UCSF Benioff Children’s Hospital Oakland |
Mark Walters |
Alpha Stem Cell Clinics Network Expansion |
University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic |
$2,292,611 |
University of California, San Francisco |
Mark Walters |
Alpha Stem Cell Clinics Network Expansion |
University of California, San Francisco (UCSF) CIRM Alpha Stem Cell Clinic |
$5,707,388 |
Stanford University |
Matthew Porteus |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease |
$4,849,363 |
Angiocrine Bioscience, Inc. |
Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 |
$5,000,000 |
University of California, San Diego |
Thomas Kipps |
Clinical Trial Stage Projects |
A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
International Alliance for Biological Standardization |
Anthony Lubiniecki |
Conference - Manage a Symposium on Pluripotent Stem Cell Manufacturing |
Basis of Standardization for Cell Therapies |
$100,000 |
University of California, San Diego |
Ezra Cohen |
Therapeutic Translational Research Projects |
Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies |
$5,795,584 |
BrainStorm Cell Therapeutics |
Ralph Kern |
Clinical Trial Stage Projects |
A Phase 3, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy & Safety of Repeated Administrations of NurOwn® in Patients with ALS |
$15,912,390 |
JDRF International |
Esther Latres |
Conference II |
JDRF Encapsulation Consortium Fall 2017 Meeting |
$42,425 |
University of California, Irvine |
Brian Cummings |
Quest - Discovery Stage Research Projects |
Identification and characterization of the optimal human neural stem cell line (hNSC) for the treatment of traumatic brain injury (TBI) 2.0. |
$1,671,213 |
Stanford University |
Gary Steinberg |
Late Stage Preclinical Projects |
Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke |
$5,300,000 |
City of Hope, Beckman Research Institute |
Markus Müschen |
Quest - Discovery Stage Research Projects |
Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,186,520 |
Cellerant Therapeutics, Inc. |
Swapna Panuganti |
Late Stage Preclinical Projects |
Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia |
$6,863,755 |
Scaled Biolabs Inc. |
Justin Cooper-White |
Quest - Discovery Stage Research Projects |
A tool for rapid development of clinical-grade protocols for dopaminergic neuronal differentiation of Parkinson’s Disease patient-derived iPSCs |
$657,528 |
SanBio, Inc. |
Bijan Nejadnik |
Clinical Trial Stage Projects |
A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke |
$18,970,000 |
University of California, San Diego |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$279,977 |
University of California, San Francisco |
Holger Willenbring |
Quest - Discovery Stage Research Projects |
Preclinical development of AAV vector-mediated in vivo hepatic reprogramming of myofibroblasts as a therapy for liver fibrosis |
$1,638,389 |
University of California, San Francisco |
Tippi MacKenzie |
Clinical Trial Stage Projects |
In Utero Hematopoietic Stem Cell Transplantation For The Treatment Of Fetuses With Alpha Thalassemia Major |
$10,906,978 |
University of California, Berkeley |
Kevin Healy |
Quest - Discovery Stage Research Projects |
Human Cardiac Chip for Assessment of Proarrhythmic Risk |
$899,581 |
City of Hope, Beckman Research Institute |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
Stanford University |
Mark Mercola |
Quest - Discovery Stage Research Projects |
Multipotent Cardiovascular Progenitor Regeneration of the Myocardium after MI |
$1,809,234 |
University of California, Davis |
Deborah Lieu |
Quest - Discovery Stage Research Projects |
Microenvironment for hiPSC-derived pacemaking cardiomyocytes |
$2,042,438 |
University of California, Los Angeles |
Caroline Kuo |
Quest - Discovery Stage Research Projects |
Targeted Gene Editing in the Treatment of X-Linked Hyper-IgM Syndrome |
$1,512,333 |
X-Therma Inc. |
Xiaoxi Wei |
Quest - Discovery Stage Research Projects |
Non-Toxic, Highly-Effective Bioinspired Cryoprotectants for On-Demand Stem Cell Therapies |
$887,883 |
University of California, Los Angeles |
Gay Crooks |
Quest - Discovery Stage Research Projects |
Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
Rumi Scientific CA |
Ali Brivanlou |
Quest - Discovery Stage Research Projects |
Discovery of therapeutics for Huntington’s Disease |
$1,399,800 |
University of California, Los Angeles |
Vaithilingaraja Arumugaswami |
Quest - Discovery Stage Research Projects |
Immunization strategies to prevent Zika viral congenital eye and brain disease |
$2,128,867 |
Sanford Burnham Prebys Medical Discovery Institute |
Alessandra Sacco |
Inception - Discovery Stage Research Projects |
Generation of expandable, self-renewing muscle stem cells for Duchenne Muscular Dystrophy |
$252,000 |
Stanford University |
Helen Blau |
Inception - Discovery Stage Research Projects |
Prodrug innovation to target muscle stem cells and enhance muscle regeneration |
$235,834 |
University of California, San Diego |
Tannishtha Reya |
Inception - Discovery Stage Research Projects |
Reprogramming human stem cells for blood cell generation |
$210,060 |
University of California, Irvine |
Janet Baulch |
Inception - Discovery Stage Research Projects |
An exosome-based translational strategy to mitigate Alzheimer’s disease neuropathology |
$157,650 |
University of Southern California |
Biju Thomas |
Inception - Discovery Stage Research Projects |
A Novel Tissue Engineering Technique to Repair Degenerated Retina |
$215,133 |
University of California, San Francisco |
Sonja Schrepfer |
Inception - Discovery Stage Research Projects |
Hypo-immunogenic cardiac patches for myocardial regeneration |
$235,818 |
American Association of Blood Banks |
Naynesh Kamani |
Conference II |
15th International Cord Blood Sympsium |
$30,000 |
Stanford University |
Samuel Strober |
Conference II |
Third International Workshop on Clinical Tolerance |
$29,500 |
University of California, Los Angeles |
Song Li |
Conference II |
The 18th Annual UC System-Wide Bioengineering Symposium |
$25,000 |
University of California, San Diego |
Karen Christman |
Therapeutic Translational Research Projects |
Injectable pro-regenerative scaffold for treating symptomatic peripheral artery disease |
$2,839,317 |
Stanford University |
Joseph Wu |
Tool Translational Research Projects |
A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific Induced Pluripotent Stem Cells for Preclinical Drug Screening |
$975,000 |
Cellular Biomedicine Group, Inc. |
Jack Wang |
Late Stage Preclinical Projects |
Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis |
$1,200,000 |
Caladrius Biosciences |
William Sietsema |
Clinical Trial Stage Projects |
Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus |
$8,175,946 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Clinical Trial Stage Projects |
Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
St. Jude Children's Research Hospital |
Stephen Gottschalk |
Clinical Trial Stage Projects |
Lentiviral Gene Therapy for Infants with X-linked Severe Combined Immunodeficiency using Autologous Bone Marrow Stem Cells and Busulfan Conditioning |
$11,924,780 |
City of Hope, Beckman Research Institute |
John Zaia |
Conference - The 2017 Alpha Stem Cell Clinic Annual Symposium |
2nd Annual Symposium of the CIRM Alpha Stem Cell Clinics Network
"Alpha Clinics - Making the Future a Reality for Stem Cell-Based Therapies" |
$79,287 |
Stanford University |
Joseph Wu |
Conference II |
2017 Stanford Drug Discovery and Stem Cell Technology Conference |
$2,359 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Targeted off-the-shelf immunotherapy to treat refractory cancers |
$1,936,936 |
University of California, Los Angeles |
John Chute |
Quest - Discovery Stage Research Projects |
Protein tyrosine phosphatase - sigma inhibitors for hematopoietic regeneration |
$2,115,735 |
University of California, San Francisco |
Julie Sneddon |
Quest - Discovery Stage Research Projects |
Designing a cellular niche for transplantation of human embryonic stem cell-derived beta cells |
$2,006,076 |
Stanford University |
Matthew Porteus |
Quest - Discovery Stage Research Projects |
Genome Editing to Correct Cystic Fibrosis Mutations in Airway Stem Cells |
$1,968,456 |
University of California, San Diego |
Alysson Muotri |
Quest - Discovery Stage Research Projects |
A treatment for Zika virus infection and neuroprotection efficacy |
$1,924,524 |
Stanford University |
Rosa Bacchetta |
Quest - Discovery Stage Research Projects |
GENE EDITING FOR FOXP3 IN HUMAN HSC |
$984,228 |
University of California, San Francisco |
Tejal Desai |
Quest - Discovery Stage Research Projects |
Thin Film Encapsulation Devices for Human Stem Cell derived Insulin Producing Cells |
$1,092,063 |
Stanford University |
Roel Nusse |
Quest - Discovery Stage Research Projects |
Preclinical development of human hepatocyte progenitor cells for cell therapy |
$1,651,211 |
University of California, Irvine |
Leslie Thompson |
Quest - Discovery Stage Research Projects |
hNSC-mediated delivery of ApiCCT1 as a candidate therapeutic for Huntington’s disease |
$1,650,263 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Quest - Discovery Stage Research Projects |
Direct Cardiac Reprogramming for Regenerative Medicine |
$2,392,157 |
Parkinson's Institute |
Birgitt Schuele |
Quest - Discovery Stage Research Projects |
CRISPR/dCas9 mutant targeting SNCA promoter for downregulation of alpha-synuclein expression as a novel therapeutic approach for Parkinson’s disease |
$1,288,415 |
jCyte, Inc |
Henry Klassen |
Clinical Trial Stage Projects |
Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa |
$8,295,750 |
Stanford University |
Robert Lowsky |
Clinical Trial Stage Projects |
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
Ankasa Regenerative Therapeutics, Inc. |
Ying Zhu |
Therapeutic Translational Research Projects |
An autologous somatic stem cell therapy for the treatment of osteonecrosis |
$2,088,780 |
University of Southern California |
Denis Evseenko |
Therapeutic Translational Research Projects |
Pluripotent stem cell-derived chondrocytes for articular cartilage repair |
$2,503,104 |
UCSF Benioff Children’s Hospital Oakland |
Mark Walters |
Therapeutic Translational Research Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$4,394,276 |
Gladstone Institutes, J. David |
Yadong Huang |
Therapeutic Translational Research Projects |
Human iPSC-derived GABAergic Progenitors for Alzheimer’s Disease Treatment |
$1,900,000 |
University of California, San Francisco |
Mark Walters |
Therapeutic Translational Research Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$60,635 |
City of Hope, Beckman Research Institute |
Paul Salvaterra |
Conference - Manage The SPARK Annual Meeting |
Manage the 2017 SPARK Annual Meeting |
$22,555 |
University of Southern California |
Justin Ichida |
Conference II |
The 7th Annual California ALS research network and PAC10 meeting |
$10,830 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$10,156,925 |
Cedars-Sinai Medical Center |
Michael Lewis |
Clinical Trial Stage Projects |
Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells |
$7,354,772 |
Orchard Therapeutics plc |
Leslie Meltzer |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$2,638,745 |
San Diego State University Foundation |
Ralph Feuer |
Conference - Manage The Bridges Annual Meeting |
2017 Bridges Annual Meeting |
$153,449 |
IQVIA, Inc. |
Amritha Jaishankar |
Translating Center |
A Translating Center designed to expedite the development and delivery of high quality stem cell therapies to patients |
$15,000,000 |
University of California, San Diego |
Stephanie Cherqui |
Late Stage Preclinical Projects |
Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis |
$5,273,189 |
Midwinter Conference of Immunologists |
Christel Uittenbogaart |
Conference II |
The 2017 Midwinter Conference of Immunologists at Asilomar |
$5,000 |
University of California, San Diego |
Robert Sah |
Conference II |
2016 Tissue Engineering and Regenerative Medicine International Society - Americas (TERMIS-AM) Conference in San Diego, CA on December 11-14, 2016 |
$40,000 |
Vitalant Research Institute |
Shibani Pati |
Conference II |
Cellular Therapies and Transfusion Medicine in Trauma and Critical Care - Looking Towards the Future |
$30,000 |
Alliance Forum Foundation |
George Hara |
Conference II |
2016 World Alliance Forum in San Francisco (WAFSF) “US-Japan Innovative Healthcare Technologies Conference” |
$20,000 |
Humacyte, Inc. |
Jeffrey Lawson |
Clinical Trial Stage Projects |
A Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
$7,625,000 |
University of California, Los Angeles |
April Pyle |
Quest - Discovery Stage Research Projects |
CRISPR/Cas9 nanoparticle enabled therapy for Duchenne Muscular Dystrophy in muscle stem cells |
$2,150,400 |
Stanford University |
Hiromitsu Nakauchi |
Quest - Discovery Stage Research Projects |
Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
University of California, Berkeley |
David Schaffer |
Quest - Discovery Stage Research Projects |
Scalable, Defined Production of Oligodendrocyte Precursor Cells to Treat Neural Disease and Injury |
$1,627,099 |
University of California, Davis |
David Segal |
Quest - Discovery Stage Research Projects |
MSC delivery of an artificial transcription factor to the brain as a treatment for Angelman Syndrome |
$1,055,319 |
Scripps Research Institute |
Jeanne Loring |
Quest - Discovery Stage Research Projects |
Autologous cell therapy for Parkinson’s disease using iPSC-derived DA neurons |
$2,299,786 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Quest - Discovery Stage Research Projects |
Use of Human iPSC-derived Endothelial Cells for Calcific Aortic Valve Disease Therapeutics |
$2,400,048 |
California Institute of Technology |
David Baltimore |
Quest - Discovery Stage Research Projects |
Immunotherapy for HIV infection using engineered hematopoietic stem/progenitor cells |
$1,569,193 |
ViaCyte, Inc. |
Kevin D'Amour |
Late Stage Preclinical Projects |
Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes |
$3,544,721 |
University of California, Los Angeles |
Sophie Deng |
Late Stage Preclinical Projects |
Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
IQVIA, Inc. |
Peter Robinson |
Accelerating Center |
An Accelerating Center designed to expedite the development and delivery of high quality stem cell therapies to patients |
$11,772,453 |
University of California, Los Angeles |
Brigitte Gomperts |
Conference - Lung Regenerative Medicine Workshop |
Stem Cells for Lung Diseases - Overcoming Barriers to Find New Therapies |
$44,548 |
University of California, San Diego |
Alysson Muotri |
Inception - Discovery Stage Research Projects |
Reverse transcriptase inhibitors as a novel therapeutic approach for neurological autoimmune disorders |
$210,060 |
University of California, Los Angeles |
Owen Witte |
Inception - Discovery Stage Research Projects |
Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
Stanford University |
Jeffrey Goldberg |
Inception - Discovery Stage Research Projects |
Embryonic Stem Cells for Corneal Endothelial Degeneration |
$235,836 |